Assessing Response to PSMA Radiopharmaceutical Therapies with Single SPECT Imaging at 24 Hours After Injection.

التفاصيل البيبلوغرافية
العنوان:	Assessing Response to PSMA Radiopharmaceutical Therapies with Single SPECT Imaging at 24 Hours After Injection.
المؤلفون:	Yadav S; Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California., Jiang F; Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California., Kurkowska S; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, British Columbia, Canada.; Department of Nuclear Medicine, Pomeranian Medical University, Szczecin, Poland., Saelee R; Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California., Morley A; Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California., Feng F; Department of Radiation Oncology, University of California San Francisco, San Francisco, California., Aggarwal R; Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, California., Lawhn-Heath C; Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California., Uribe C; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, British Columbia, Canada.; Department of Radiology, University of British Columbia, Vancouver, British Columbia, Canada.; Department of Molecular Imaging and Therapy, BC Cancer, Vancouver, British Columbia, Canada., Hope TA; Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California; thomas.hope@ucsf.edu.; Department of Radiology, San Francisco VA Medical Center, San Francisco, California; and.; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.
المصدر:	Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2024 May 09. Date of Electronic Publication: 2024 May 09.
Publication Model:	Ahead of Print
نوع المنشور:	Journal Article
اللغة:	English
بيانات الدورية:	Publisher: Society of Nuclear Medicine Country of Publication: United States NLM ID: 0217410 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1535-5667 (Electronic) Linking ISSN: 01615505 NLM ISO Abbreviation: J Nucl Med Subsets: MEDLINE
أسماء مطبوعة:	Publication: Reston, VA : Society of Nuclear Medicine Original Publication: [Chicago, Ill.] : S.N. Turiel & Assoc.
مستخلص:	Understanding the relationship between lesion-absorbed dose and tumor response in ¹⁷⁷ Lu-PSMA-617 radiopharmaceutical therapies (RPTs) remains complex. We aimed to investigate whether baseline lesion-absorbed dose can predict lesion-based responses and to explore the connection between lesion-absorbed dose and prostate-specific antigen (PSA) response. Methods: In this retrospective study, we evaluated 50 patients with 335 index lesions undergoing ¹⁷⁷ Lu-PSMA-617 RPT, who had dosimetry analysis performed on SPECT/CT at 24 h after cycles 1 and 2. First, we identified the index lesions for each patient and measured the lesion-based absorbed doses. Lesion-based response was calculated after cycle 2. Additionally, PSA50 response (a decline of 50% from baseline PSA) after cycle 2 was also calculated. The respective responses for mean and maximum absorbed doses and prostate-specific membrane antigen (PSMA) volumetric intensity product (VIP-PSMA) at cycles 1 and 2 were termed SPECT mean , SPECT maximum , and SPECT VIP-PSMA , respectively. Results: Of the 50 patients reviewed, 46% achieved a PSA50 response after cycle 2. Of the 335 index lesions, 58% were osseous, 32% were lymph nodes, and 10% were soft-tissue metastatic lesions. The SPECT lesion-based responses were higher in PSA responders than in nonresponders (SPECT mean response of 46.8% ± 26.1% vs. 26.2% ± 24.5%, P = 0.007; SPECT maximum response of 45% ± 25.1% vs. 19% ± 27.0%, P = 0.001; SPECT VIP-PSMA response of 49.2% ± 30.3% vs. 14% ± 34.7%, P = 0.0005). An association was observed between PSA response and SPECT VIP-PSMA response ( R ² = 0.40 and P < 0.0001). A limited relationship was found between baseline absorbed dose measured with a 24-h single time point and SPECT lesion-based response ( R ² = 0.05, P = 0.001, and R ² = 0.03, P = 0.007, for mean and maximum absorbed doses, respectively). Conclusion: In this retrospective study, quantitative lesion-based response correlated with patient-level PSA response. We observed a limited relationship between baseline absorbed dose and lesion-based responses. Most of the variance in response remains unexplained solely by baseline absorbed dose. Establishment of a dose-response relationship in RPT with a single time point at 24 h presented some limitations. (© 2024 by the Society of Nuclear Medicine and Molecular Imaging.)
فهرسة مساهمة:	Keywords: SPECT/CT; dosimetry; prostate cancer; radiopharmaceutical therapy; response to RPT; theranostics
تواريخ الأحداث:	Date Created: 20240509 Latest Revision: 20240509
رمز التحديث:	20240510
DOI:	10.2967/jnumed.123.267208
PMID:	38724282
قاعدة البيانات:	MEDLINE

الوصف
تدمد:	1535-5667
DOI:	10.2967/jnumed.123.267208